Therefore, the data presented in this study provide substantial support for the evaluation of HP-BCD as an antiretroviral drug potentially able to reduce viral replication (29, –, 32) and control HIV-associated chronic immune activation that aggravates HIV comorbidities and AIDS progression. This evidence concerns the gene CYP4V2 and AIDS.